BioSpace News Archive

New Financing of $24 Million Fully Funds the Phase 2 Clinical Program for Lead Candidate VLX-1005

For the first time in Hillsborough County, Tampa General Hospital physicians diagnosed and removed a cancerous tumor from a patient’s lung during a single surgery, saving critical time between procedures that might otherwise be weeks apart.

ImmuCell Corporation, a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced that Bryan K. Gathagan has been appointed to its Board of Directors.

Roivant Sciences announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Phase 2b study of RVT-3101 in ulcerative colitis.

GSK plc announced that the US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted in favor of recommending the use of AREXVY in adults aged 60 and older using shared clinical decision making.

ValnevaSE announced that all the resolutions recommended by the Management Board were approved by the shareholders at its Annual General Meeting held in Lyon, France.

RLS, Inc., the third-largest nuclear medicine pharmacy network in the US, announced the appointments of Janet Otts-Watson as Vice President of Sales and Marketing, and Renee Wolf as Executive Director of Human Resources.

Cure Brain Cancer Foundation and Qatar Cancer Society are pleased to announce the start of discussions of a strategic collaborative partnership that will play a vital role in progressing cancer research, advancements, and treatments globally.

Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, announced that it is set to join the broad-market Russell 3000 Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens on June 26, 2023, according to a preliminary list of additions posted May 19, 2023.

Avidity Biosciences, Inc. announced that on June 20, 2023, the Human Capital Management Committee of Avidity’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 23,650 shares of its common stock and 11,825 restricted stock units to four new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.